OrbusNeich granted stent patent; expands Bos Sci case

OrbusNeich Medical, a developer and marketer of medical devices for the treatment of cardiovascular diseases, was granted U.S. Patent No. 7,682,384 B2, entitled ‘Stent with Helical Elements,’ relating to an expandable stent comprised of a plurality of helical segments. The Hong Kong-based company has identified unlicensed use by Boston Scientific of certain technologies protected under U.S. Patent No. 7,682,384 B2.

OrbusNeich said it believes that its previously announced infringement claims against Boston Scientific in the U.S. District Court for the District of Massachusetts, specifically related to Boston Scientific's Liberte and Taxus Liberte stents, could be expanded to include the newly granted patent. As a result, the company today filed with the court a motion to amend its existing complaint against the Natick, Mass.-based Boston Scientific.

"We are committed to taking all appropriate actions to ensure that our proprietary technology and extensive research and development efforts are to the benefit of OrbusNeich's investors, employees and physician customers and their patients – not those of competitors," said Al Novak, president and CEO of OrbusNeich.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup